Phaseline

Companies › CSPC Megalith Biopharmaceutical

CSPC Megalith Biopharmaceutical: clinical trials, targets and expected readouts

8 active drug programs in 13 registered trials: 6 Phase 1, 5 Phase 2, 2 Phase 3; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SYS6043
B7-H3-targeted antibody-drug conjugate
B7H3Phase 3Platinum-resistant Ovarian Cancer; Advanced/Metastatic Solid TumorsDec 2027
SYS6010–Phase 3EGFR-mutated Locally Advanced or Metastatic NSCLC; Head and Neck Squamous Cell CarcinomaJun 2028
SYS6041
anti-FOLR1 antibody-drug conjugate
FOLR1Phase 2Ovarian Cancer; Advanced Solid TumorsMar 2027
SYS6023–Phase 2Advanced Breast Cancer; Advanced Solid TumorNov 2027
Enlonstobart
recombinant human anti-PD-1 monoclonal antibody
PDCD1Phase 2Ovarian Cancer; Head and Neck Squamous Cell CarcinomaApr 2028
SYS6005–Phase 1B-cell MalignanciesJan 2027
SYS6040 for injection–Phase 1Small Cell Lung CancerFeb 2027
SYS6045
HER2-targeted therapy
ERBB2Phase 1Advanced Solid TumorsJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06927986SYS6010Phase 3EGFR-mutated Locally Advanced or Metastatic NSCLCOncologyJul 2026
NCT06958679SYS6005Phase 1B-cell MalignanciesOncologyJan 2027
NCT06970795SYS6040 for injectionPhase 1Small Cell Lung CancerOncologyFeb 2027
NCT07744763SYS6041Phase 1Advanced Solid TumorsOncologyMar 2027
NCT07122063SYS6045Phase 1Advanced Solid TumorsOncologyJul 2027
NCT07597629SYS6023Phase 2Advanced Breast CancerOncologyNov 2027
NCT07415863SYS6043Phase 1Advanced/Metastatic Solid TumorsOncologyDec 2027
NCT07714668EnlonstobartPhase 2Ovarian CancerOncologyApr 2028
NCT07714668SYS6041Phase 2Ovarian CancerOncologyApr 2028
NCT07254585SYS6010Phase 2Head and Neck Squamous Cell CarcinomaOncologyJun 2028
NCT07254585EnlonstobartPhase 2Head and Neck Squamous Cell CarcinomaOncologyJun 2028
NCT07110883SYS6023Phase 1Advanced Solid TumorOncologyOct 2028
NCT07708753SYS6043Phase 3Platinum-resistant Ovarian CancerOncologyOct 2029

Targets

ERBB2 (1) B7H3 (1) PDCD1 (1) FOLR1 (1)

Companies with the same targets

Beijing Biotech Shenyang Sunshine Pharmaceutical AstraZeneca Roche Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Akeso Jiangsu HengRui Medicine Innovent Biologics (Suzhou) BioNTech SE

Companies built like this

DualityBio RemeGen CStone Pharmaceuticals Shenyang Sunshine Pharmaceutical TaiRx

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.